GT Biopharma, Inc.

US$4.42As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GTBPHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (68.79%)
Div yield —
ROE (113.52%)
Biotechnology
Beta (5Y) 0.83
PE TTM —
TSR TTM (71.81%)
Mkt cap US$7.975M
ROIC (243.52%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.72
6.68%
146.98%
Hold 12|3|3|4|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.07
0.07
0.07
0.07
10.99%
9.92%
20.57%
14.10%
Revenue$M
0.707
0.687
0.710
0.719
11.47%
3.31%
2.94%
0.03%
Peers (US$7.975M)
Cap (US$)
PE
7.291M
—
8.031M
—
Capital
TTM
5Y
10Y
Leveragex
0.265
0.322
0.285
EBIT/Intx
5.718
0.119
0.124
Own earn%
(1.29)
(3.19)
(1.62)
Sh yield%
35.07
19.83
16.73
Owners
Insiders/Inst%
7.28
35.93
Short interest%
3.42
SBC / revenue%
2.77
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
4–14
$1 testx
—
Incr. ROIC%
5